| ATHS |
|
atherosclerosis susceptibility (lipoprotein associated)
|
|
|
0.551 |
0.769 |
| BTF3P11 |
|
basic transcription factor 3 pseudogene 11
|
|
|
0.519 |
0.731 |
| HLA-DRB9 |
|
major histocompatibility complex, class II, DR beta 9 (pseudogene)
|
|
|
0.682 |
0.654 |
| HTC2 |
|
hypertrichosis 2 (generalized, congenital)
|
|
|
0.392 |
0.808 |
| MT1JP |
|
metallothionein 1J, pseudogene
|
|
|
0.588 |
0.731 |
| NM |
|
neutrophil migration
|
|
|
0.473 |
0.808 |
| PTMAP4 |
|
prothymosin alpha pseudogene 4
|
|
|
0.638 |
0.731 |
| PVT1 |
|
Pvt1 oncogene
|
|
|
0.495 |
0.731 |
| TERC |
|
telomerase RNA component
|
|
|
0.471 |
0.846 |
| KCNQ1OT1 |
|
KCNQ1 opposite strand/antisense transcript 1
|
|
|
0.534 |
0.731 |
| MBL3P |
|
mannose-binding lectin family member 3, pseudogene
|
|
|
0.518 |
0.769 |
| HDL3 |
|
Huntington-like neurodegenerative disorder 2
|
|
|
0.663 |
0.423 |
| MEG3 |
|
maternally expressed 3
|
|
|
0.471 |
0.846 |
| GAS5 |
|
growth arrest specific 5
|
|
|
0.497 |
0.808 |
| PWAR1 |
|
Prader Willi/Angelman region RNA 1
|
|
|
0.490 |
0.769 |
| CASC2 |
|
cancer susceptibility 2
|
|
|
0.612 |
0.462 |
| COPD |
|
Pulmonary disease, chronic obstructive, severe early-onset
|
|
|
0.456 |
0.885 |
| H19 |
|
H19 imprinted maternally expressed transcript
|
|
|
0.494 |
0.923 |
| HNF1A-AS1 |
|
HNF1A antisense RNA 1
|
|
|
0.621 |
0.538 |
| MIF-AS1 |
|
MIF antisense RNA 1
|
|
|
0.663 |
0.577 |
| PWAR4 |
|
Prader Willi/Angelman region RNA 4
|
|
|
0.573 |
0.769 |
| MALAT1 |
|
metastasis associated lung adenocarcinoma transcript 1
|
|
|
0.435 |
0.846 |
| LINC01194 |
|
long intergenic non-protein coding RNA 1194
|
|
|
0.470 |
0.769 |
| MIR106B |
|
microRNA 106b
|
|
|
0.523 |
0.808 |
| MIR107 |
|
microRNA 107
|
|
|
0.543 |
0.769 |